MUMBAI, India, June 19 -- Intellectual Property India has published a patent application (202617055376 A) filed by Rensselaer Polytechnic Institute; and Cedars-Sinai Medical Center on April 30, 2026, for Systems And Methods Of Point-Of-Care Testing For Urinary Biomarkers Including Ultrasensitive Immunomag-Crispr Lateral Flow Assays.
Inventors include Kwon, Seok-Joon; Lee, Inseon; Dordick, Jonathan, Seth; and Heeger, Peter.
The application for the patent was published on June 05, 2026, under issue no. 23/2026.
Abstract: Target biomarkers, e.g., chemokine ligand 9 (CXCL9), chemokine ligand 10 (CXCL10), etc., are detected in human urinary samples via magnetic particle-antibody complexes. These complexes bind to the target biomarkers in the sample and enable magnetic enrichment of the biomarkers into a portion of that sample. Sandwich structure complexes are prepared via further contact with DNA barcode-antibody complexes that include CRISPR/Cas recognition sites, e.g., for Cas9, Casl2a, Cast 3 a, etc. Cas-RNA complexes activate upon binding with the DNA barcodes, resulting in cleavage of reporter complexes, e.g., fluorophore-biotin (FB) reporter, fluorophore-quencher (FQ) reporter, that can be detected as an indicator of biomarker concentration in the sample. A limit of detection for urinary biomarkers of 18 pg/mL was demonstrated in a patient sample via naked-eye detection using commercially available lateral flow assay test strips configured to bind cleaved portions of the reporter complexes.
Disclaimer: Curated by HT Syndication.
